Calliditas has announced the final outcome of simplified mandatory offer to the shareholders of Genkyotex.

Calliditas Therapeutics submitted a simplified public mandatory offer to the shareholders of Genkyotex on 26 November 2020. After the end of the acceptance period on December 11, Calliditas now controls 86.2 percent of the shares in Genkyotex.

Calliditas acquired 7,236,515 ordinary shares in Genkyotex on November 3, 2020, corresponding to 62.7 percent of the share capital and voting rights, from Genkyotex’s largest shareholders and management group. On November 26, 2020, Calliditas submitted a simplified public mandatory cash offer of EUR 2.80 and non-transferable contingent rights, per share to the remaining shareholders in Genkyotex.

In the final outcome after the acceptance period, 2,885,161 shares have been tendered into the offer. As result Calliditas controls a total of 10,121,676 shares in Genkyotex, which corresponds to 86.2 percent of the share capital and the total number of votes in Genkyotex.

Photo of Renée Aguiar-Lucander, CEO of Calliditas